GLS · Gelesis Holdings Inc
Acquired Company
Capstar Special Purpose Acquisition Corp. completed its business combination with Gelesis on 1/13/2022, and Gelesis Holdings, Inc. began trading as GLS on 1/14/2022.
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its non-systemic superabsorbent hydrogels are the first and only made entirely from naturally derived building blocks, and they are inspired by the composition (i.e., water & cellulose) and mechanical properties (e.g., elasticity or firmness) of raw vegetables. They are conveniently administered in capsules to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system. Its portfolio includes Plenity®, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$0.16
Open
N/A
Volume
N/A
Day Range
N/A - N/A
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
52.70%
Institutional Own.
29.38%
Qtr Updated
Jun 30th 2024
